Literature DB >> 19443720

Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy.

Patrick Yu-Wai-Man1, Vanessa J Davies, Malgorzata J Piechota, Lynsey M Cree, Marcela Votruba, Patrick F Chinnery.   

Abstract

PURPOSE: The majority of patients with autosomal dominant optic atrophy (DOA) harbor pathogenic OPA1 mutations and certain missense mutations, mostly within the GTPase domain, have recently been shown to cause multiple mitochondrial DNA (mtDNA) deletions in skeletal muscle. This raises the possibility that the optic neuropathy could be the result of secondary mtDNA defects accumulating within retinal ganglion cells (RGCs). To explore this hypothesis, the authors looked for evidence of mitochondrial dysfunction in a mouse model of DOA and documented the visual and neurologic progression in aging mutant mice.
METHODS: Visual function was assessed with a rotating optokinetic (OKN) drum at ages 13 and 18 months and neurologic phenotyping was performed using the primary SHIRPA screen at age 13 months, comparing mutant Opa1(+/)(-) mice with wild-type C57Bl/6 mice. The presence of cytochrome c oxidase (COX) deficiency and multiple mtDNA deletions was investigated in gastrocnemius muscle and eye specimens harvested from 2- and 11-month-old Opa1(+/+) and Opa1(+/)(-) mice.
RESULTS: At age 13 months, Opa1(+/)(-) mice had a statistically significant reduction in OKN responses compared to C57Bl/6 controls with both 2 degrees and 8 degrees gratings (P < 0.001). At age 18 months, the difference between the two groups was significant for the 8 degrees grating (P = 0.003) but not for the 2 degrees grating (P = 0.082). Opa1(+/)(-) mice did not exhibit any significant neuromuscular deficits and no COX deficient areas or secondary mtDNA deletions were identified in skeletal muscle or the RGC layer. There was also no evidence of significant mtDNA depletion or proliferation in skeletal muscle from Opa1(+/)(-) mice.
CONCLUSIONS: COX deficiency and mtDNA abnormalities do not contribute to optic nerve dysfunction in pure DOA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443720      PMCID: PMC4034167          DOI: 10.1167/iovs.09-3634

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  26 in total

Review 1.  Mitochondrial DNA--all things bad?

Authors:  R N Lightowlers; H T Jacobs; O A Kajander
Journal:  Trends Genet       Date:  1999-03       Impact factor: 11.639

2.  OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.

Authors:  Claudia Zanna; Anna Ghelli; Anna Maria Porcelli; Mariusz Karbowski; Richard J Youle; Simone Schimpf; Bernd Wissinger; Marcello Pinti; Andrea Cossarizza; Sara Vidoni; Maria Lucia Valentino; Michela Rugolo; Valerio Carelli
Journal:  Brain       Date:  2008-02       Impact factor: 13.501

3.  The natural history of OPA1-related autosomal dominant optic atrophy.

Authors:  A C Cohn; C Toomes; A W Hewitt; L S Kearns; C F Inglehearn; J E Craig; D A Mackey
Journal:  Br J Ophthalmol       Date:  2008-07-24       Impact factor: 4.638

4.  eOPA1: an online database for OPA1 mutations.

Authors:  Marc Ferré; Patrizia Amati-Bonneau; Yves Tourmen; Yves Malthièry; Pascal Reynier
Journal:  Hum Mutat       Date:  2005-05       Impact factor: 4.878

5.  Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1.

Authors:  Silvio Ferraris; Susanna Clark; Emanuela Garelli; Guido Davidzon; Steven A Moore; Randy H Kardon; Rachelle J Bienstock; Matthew J Longley; Michelangelo Mancuso; Purificación Gutiérrez Ríos; Michio Hirano; William C Copeland; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2008-01

Review 6.  Focus on molecules: the OPA1 protein.

Authors:  Vanessa Davies; Marcela Votruba
Journal:  Exp Eye Res       Date:  2006-03-23       Impact factor: 3.467

7.  OPA1 in multiple mitochondrial DNA deletion disorders.

Authors:  J D Stewart; G Hudson; P Yu-Wai-Man; E L Blakeley; L He; R Horvath; P Maddison; A Wright; P G Griffiths; D M Turnbull; R W Taylor; P F Chinnery
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

8.  Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance.

Authors:  Gavin Hudson; Patrizia Amati-Bonneau; Emma L Blakely; Joanna D Stewart; Langping He; Andrew M Schaefer; Philip G Griffiths; Kati Ahlqvist; Anu Suomalainen; Pascal Reynier; Robert McFarland; Douglass M Turnbull; Patrick F Chinnery; Robert W Taylor
Journal:  Brain       Date:  2007-12-07       Impact factor: 13.501

9.  High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease.

Authors:  Andreas Bender; Kim J Krishnan; Christopher M Morris; Geoffrey A Taylor; Amy K Reeve; Robert H Perry; Evelyn Jaros; Joshua S Hersheson; Joanne Betts; Thomas Klopstock; Robert W Taylor; Douglass M Turnbull
Journal:  Nat Genet       Date:  2006-04-09       Impact factor: 38.330

Review 10.  Inherited mitochondrial optic neuropathies.

Authors:  P Yu-Wai-Man; P G Griffiths; G Hudson; P F Chinnery
Journal:  J Med Genet       Date:  2008-11-10       Impact factor: 6.318

View more
  10 in total

Review 1.  Why mitochondria must fuse to maintain their genome integrity.

Authors:  Sara Vidoni; Claudia Zanna; Michela Rugolo; Emmanuelle Sarzi; Guy Lenaers
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

Review 2.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 3.  Mitochondrial Diseases Part II: Mouse models of OXPHOS deficiencies caused by defects in regulatory factors and other components required for mitochondrial function.

Authors:  Luisa Iommarini; Susana Peralta; Alessandra Torraco; Francisca Diaz
Journal:  Mitochondrion       Date:  2015-01-29       Impact factor: 4.160

4.  Multi-system neurological disease is common in patients with OPA1 mutations.

Authors:  P Yu-Wai-Man; P G Griffiths; G S Gorman; C M Lourenco; A F Wright; M Auer-Grumbach; A Toscano; O Musumeci; M L Valentino; L Caporali; C Lamperti; C M Tallaksen; P Duffey; J Miller; R G Whittaker; M R Baker; M J Jackson; M P Clarke; B Dhillon; B Czermin; J D Stewart; G Hudson; P Reynier; D Bonneau; W Marques; G Lenaers; R McFarland; R W Taylor; D M Turnbull; M Votruba; M Zeviani; V Carelli; L A Bindoff; R Horvath; P Amati-Bonneau; P F Chinnery
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

Review 5.  Disturbed mitochondrial dynamics and neurodegenerative disorders.

Authors:  Florence Burté; Valerio Carelli; Patrick F Chinnery; Patrick Yu-Wai-Man
Journal:  Nat Rev Neurol       Date:  2014-12-09       Impact factor: 42.937

6.  Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy.

Authors:  Nicole J Van Bergen; Jonathan G Crowston; Lisa S Kearns; Sandra E Staffieri; Alex W Hewitt; Amy C Cohn; David A Mackey; Ian A Trounce
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

Review 7.  Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics.

Authors:  Marcel V Alavi; Nico Fuhrmann
Journal:  Mol Neurodegener       Date:  2013-09-25       Impact factor: 14.195

8.  Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance.

Authors:  Gerald Pfeffer; Gráinne S Gorman; Helen Griffin; Marzena Kurzawa-Akanbi; Emma L Blakely; Ian Wilson; Kamil Sitarz; David Moore; Julie L Murphy; Charlotte L Alston; Angela Pyle; Jon Coxhead; Brendan Payne; George H Gorrie; Cheryl Longman; Marios Hadjivassiliou; John McConville; David Dick; Ibrahim Imam; David Hilton; Fiona Norwood; Mark R Baker; Stephan R Jaiser; Patrick Yu-Wai-Man; Michael Farrell; Allan McCarthy; Timothy Lynch; Robert McFarland; Andrew M Schaefer; Douglass M Turnbull; Rita Horvath; Robert W Taylor; Patrick F Chinnery
Journal:  Brain       Date:  2014-04-10       Impact factor: 13.501

9.  Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.

Authors:  Y Kushnareva; Y Seong; A Y Andreyev; T Kuwana; W B Kiosses; M Votruba; D D Newmeyer
Journal:  Cell Death Dis       Date:  2016-07-28       Impact factor: 8.469

10.  OPA1 deficiency accelerates hippocampal synaptic remodelling and age-related deficits in learning and memory.

Authors:  Ryan J Bevan; Pete A Williams; Caroline T Waters; Rebecca Thirgood; Amanda Mui; Sharon Seto; Mark Good; James E Morgan; Marcela Votruba; Irina Erchova
Journal:  Brain Commun       Date:  2020-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.